Dulaglutide
Also known as: Trulicity, LY2189265
Once-weekly GLP-1 receptor agonist, FDA-approved in 2014 as Trulicity for type 2 diabetes and cardiovascular risk reduction. Prescription medication.
Last updated
Mechanism of Action
Dulaglutide consists of two GLP-1 analog peptides fused to a modified human IgG4 Fc fragment. The large fusion protein resists DPP-4 breakdown and is cleared slowly, allowing once-weekly dosing. It activates the GLP-1 receptor to increase glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and reduce appetite.
- Half-life
- ~5 days
- Administration Routes
- Subcutaneous
- Research Status
- Clinical
Reported Benefits
- Improves glycemic control in adults and children 10 years and older with type 2 diabetes
- Reduced major adverse cardiovascular events in the REWIND trial
- Modest weight reduction
Potential Side Effects
- Nausea, vomiting, diarrhea and abdominal pain
- Decreased appetite
- Boxed warning: thyroid C-cell tumors in rodents
- Pancreatitis and gallbladder disease (warnings)
- Hypoglycemia when combined with insulin or sulfonylureas
Common Dosing
Labeled dosing starts at 0.75 mg subcutaneously once weekly and can be increased stepwise to 1.5, 3 or 4.5 mg once weekly for additional glycemic control. Dosing is set and supervised by the prescribing clinician.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Serious hypersensitivity to dulaglutide
No documented stacking partners for Dulaglutide yet.
- View
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
2019
- View
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
2021
- View
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
2022